Blood miRNA expression pattern is a possible risk marker for natalizumab-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Background: Natalizumab has shown its efficacy in reducing multiple sclerosis (MS) relapses and progression of disability; however, it has been associated with an increased risk of developing progressive multifocal leukoencephalopathy (PML). The differential expression of microRNA (miRNA), the small non-coding RNAs that regulate gene expression, in natalizumab-treated patients has been reported and miRNA have also been described as good candidates for disease biomarkers. Objective: To characterize the effect of natalizumab therapy on the miRNA expression pattern and to search for miRNAs that can predict PML on an individual basis. Methods: The expression of 754 microRNAs was measured in blood samples from 19 relapsing–remitting MS patients at three time points during natalizumab therapy, using TaqMan OpenArray panels. Two patients included in this study developed PML after more than 2 years of therapy. Results: We found that the expression level of three miRNAs (let-7c, miR-125a-5p and miR-642) was affected after 6 months of therapy (t6). Furthermore, we observed a differential expression of another three miRNAs (miR-320, miR-320b and miR-629) between the PML and non-PML groups after 12 months of treatment (t12); and a positive correlation was found between therapy time and the expression of miR-320. Conclusions: Natalizumab modified the expression levels of three miRNAs after a 6-month treatment. We suggest miR-320, miR-320b and miR-629 as possible biomarkers for individual PML risk assessment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bindea, G., Mlecnik, B., Hackl, H., Charoentong, P., Tosolini, M., Kirilovsky, A., Fridman, W.-H., Pagès, F., Trajanoski, Z., & Galon, J. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp101 · Cited by 6,280
Reijerkerk, A., Lopez-Ramirez, M. A., van het Hof, B., Drexhage, J. A. R., Kamphuis, W. W., Kooij, G., Vos, J. B., van der Pouw Kraan, T. C. T. M., van Zonneveld, A. J., Horrevoets, A. J., et al. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.3965-12.2013 · Cited by 138
Cited by
Plavina, T., Subramanyam, M., Bloomgren, G., Richman, S., Pace, A., Lee, S., Schlain, B., Campagnolo, D., Belachew, S., & Ticho, B. (2014) · Annals of Neurology · doi:10.1002/ana.24286 · Cited by 438
Applications of Phyto-Nanotechnology for the Treatment of Neurodegenerative Disorders
Bhattacharya, T., Soares, G. A. B. E., Chopra, H., Rahman, M. M., Hasan, Z., Swain, S. S., & Cavalu, S. (2022) · Materials · doi:10.3390/ma15030804 · Cited by 259
Liguori, M., Nuzziello, N., Licciulli, F., Consiglio, A., Simone, M., Viterbo, R. G., Creanza, T. M., Ancona, N., Tortorella, C., Margari, L., et al. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddx385 · Cited by 83
Piket, E., Zheleznyakova, G. Y., Kular, L., & Jagodic, M. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.04.002 · Cited by 79
Regev, K., Healy, B. C., Khalid, F., Paul, A., Chu, R., Tauhid, S., Tummala, S., Diaz-Cruz, C., Raheja, R., Mazzola, M. A., et al. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2016.5197 · Cited by 68
Metadata
- Authors
- Muñoz-Culla, M., Irizar, H., Castillo-Triviño, T., Sáenz-Cuesta, M., Sepúlveda, L., Lopetegi, I., de Munain, A. L., Olascoaga, J., Baranzini, S., & Otaegui, D.
- Venue
- Multiple Sclerosis Journal
- Publisher
- SAGE Publications
- Published
- 2014-05-22
- Volume
- 20
- Issue
- 14
- Pages
- 1851-1859
- ISSN
- 1352-4585 (ISSN-L)
- 1477-0970
- OpenAlex
- W2146528296
- Cited by
- 56
- References
- 2
- FWCI
- 4.02
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Blood miRNA expression pattern is a possible risk marker for natalizumab-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients. https://app.cochat.ai/papers/10.1177/1352458514534513
- The paper
- Muñoz-Culla, M., Irizar, H., Castillo-Triviño, T., Sáenz-Cuesta, M., Sepúlveda, L., Lopetegi, I., de Munain, A. L., Olascoaga, J., Baranzini, S., & Otaegui, D. (2014). Blood miRNA expression pattern is a possible risk marker for natalizumab-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients. Multiple Sclerosis Journal. https://doi.org/10.1177/1352458514534513
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.